drugset / Trial / NCT02462850

A Multi-Center Actual-Use Study on the Safety of CL 108 for the Treatment of Moderate to Severe Acute Pain Associated With Osteoarthritis of the Knee or Hip

NCT02462850

Phase 3 Completed 178 enrolled Charleston Laboratories, Inc
NaSingle-groupOpen-labelTreatment

Summary

The purpose of CLCT-006, a multi-center open-label study, is to evaluate the safety of CL-108 (hydrocodone 7.5 mg/APAP 325 mg, promethazine 12.5 mg) for the treatment of moderate to severe acute pain ("flare") associated with osteoarthritis of the knee or hip under actual conditions of use.

Timeline

Start
2014-10
Primary completion
2015-01
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetaminophen Small molecule 325 mg
Subject Hydrocodone Unknown 7.5 mg
Subject Promethazine Small molecule 12.5 mg

Indications

No indication recorded.